NCT05409378View on ClinicalTrials.gov

HLT® Meridian® TAVR Valve System Early Feasibility Study for Aortic Regurgitation

NAWithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 8, 2022

Primary Completion Date

January 20, 2023

Study Completion Date

January 20, 2023

Conditions
Aortic Regurgitation
Interventions
DEVICE

The HLT® Meridian® TAVR Valve (Meridian® with TriVentTM Anticalcification Treatment Valve and Pathfinder® Delivery System)

Aortic valve replacement with the HLT Meridian TAVR Valve to treat aortic regurgitation

Trial Locations (3)

43210

Ohio State University Wexner Medical Center, Columbus

45219

The Christ Hospital, Cincinnati

60611

Northwestern University, Chicago

Sponsors

Lead Sponsor

HLT Inc.
All Listed Sponsors
lead

HLT Inc.

INDUSTRY

NCT05409378 - HLT® Meridian® TAVR Valve System Early Feasibility Study for Aortic Regurgitation | Biotech Hunter | Biotech Hunter